Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis

Background To evaluate the efficacy and safety of rituximab-based combination therapy for Waldenstrom macroglobulinemia (WM), we conducted this meta-analysis by pooling the rates of overall response, major response, complete response, and grade ≥3 hematological adverse events.